Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?
Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients with Binet stage A B-CLL, and these values wer...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2009/287974 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568524573245440 |
|---|---|
| author | Stefano Molica Giovanna Digiesi Angelo Vacca Rosanna Mirabelli Katia Todoerti Caterina Battaglia Fortunato Morabito Antonino Neri Domenico Ribatti |
| author_facet | Stefano Molica Giovanna Digiesi Angelo Vacca Rosanna Mirabelli Katia Todoerti Caterina Battaglia Fortunato Morabito Antonino Neri Domenico Ribatti |
| author_sort | Stefano Molica |
| collection | DOAJ |
| description | Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients with Binet stage A B-CLL, and these values were retrospectively correlated with bone marrow (BM) microvessel area and serum levels of vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiogenin, PECAM-1 (CD31), matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), syndecan-1, and the percentage of CD38+ or ZAP-70+ CLL cells. The positive correlation between serum levels of adiponectin and VEGF (P=.03) does not translate into an increase of the extent of BM angiogenesis (P=.404), FGF-2 (P=.348), angiogenin (P=.402), and CD31 (P=.248) serum concentrations. Accordingly, IL-8 (P=.175), syndecan-1 (P=.06), and MMP-9 (P=.144) circulating levels were not likely to reflect adiponectin concentration. Furthermore, patients with higher levels of adiponectin had a more favorable biological profile as defined by a lower number of both CD38− (r=−0.294; P=.02) and ZAP-70+ (r=−0.285; P=.04). Finally, we evaluated the presence of adiponectin in B-CLL cells at gene expression level. RMA intensity values for adiponectin gene transcript denote a homogeneous low expression in B-CLL cells, whereas VEGF transcript was highly expressed with a degree of interpatient variability. Overall, these data seem to indicate that adiponectin could be involved as an antiangiogenic factor in B-CLL. |
| format | Article |
| id | doaj-art-c1ce6009d1f14821ac0cedc2001a4c2c |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-c1ce6009d1f14821ac0cedc2001a4c2c2025-02-03T00:58:53ZengWileyAdvances in Hematology1687-91041687-91122009-01-01200910.1155/2009/287974287974Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?Stefano Molica0Giovanna Digiesi1Angelo Vacca2Rosanna Mirabelli3Katia Todoerti4Caterina Battaglia5Fortunato Morabito6Antonino Neri7Domenico Ribatti8Medical Oncology Unit, Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, ItalyDepartment of Clinical Pathology, IRCCS Regina Elena, Roma, ItalyDepartment of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, ItalyMedical Oncology Unit, Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, ItalyLaboratorio di Genetica Molecolare, IRCCS Policlinico, Milano, ItalyMedical Oncology Unit, Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, ItalyDepartment of Hematology, Azienda Ospedaliera Verona, Cosenza, ItalyLaboratorio di Genetica Molecolare, IRCCS Policlinico, Milano, ItalyDepartment of Human Anatomy and Histology, University of Bari Medical School, Bari, ItalyAngiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients with Binet stage A B-CLL, and these values were retrospectively correlated with bone marrow (BM) microvessel area and serum levels of vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiogenin, PECAM-1 (CD31), matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), syndecan-1, and the percentage of CD38+ or ZAP-70+ CLL cells. The positive correlation between serum levels of adiponectin and VEGF (P=.03) does not translate into an increase of the extent of BM angiogenesis (P=.404), FGF-2 (P=.348), angiogenin (P=.402), and CD31 (P=.248) serum concentrations. Accordingly, IL-8 (P=.175), syndecan-1 (P=.06), and MMP-9 (P=.144) circulating levels were not likely to reflect adiponectin concentration. Furthermore, patients with higher levels of adiponectin had a more favorable biological profile as defined by a lower number of both CD38− (r=−0.294; P=.02) and ZAP-70+ (r=−0.285; P=.04). Finally, we evaluated the presence of adiponectin in B-CLL cells at gene expression level. RMA intensity values for adiponectin gene transcript denote a homogeneous low expression in B-CLL cells, whereas VEGF transcript was highly expressed with a degree of interpatient variability. Overall, these data seem to indicate that adiponectin could be involved as an antiangiogenic factor in B-CLL.http://dx.doi.org/10.1155/2009/287974 |
| spellingShingle | Stefano Molica Giovanna Digiesi Angelo Vacca Rosanna Mirabelli Katia Todoerti Caterina Battaglia Fortunato Morabito Antonino Neri Domenico Ribatti Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia? Advances in Hematology |
| title | Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia? |
| title_full | Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia? |
| title_fullStr | Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia? |
| title_full_unstemmed | Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia? |
| title_short | Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia? |
| title_sort | does adiponectin act as an antiangiogenic factor in b cell chronic lymphocytic leukemia |
| url | http://dx.doi.org/10.1155/2009/287974 |
| work_keys_str_mv | AT stefanomolica doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia AT giovannadigiesi doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia AT angelovacca doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia AT rosannamirabelli doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia AT katiatodoerti doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia AT caterinabattaglia doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia AT fortunatomorabito doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia AT antoninoneri doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia AT domenicoribatti doesadiponectinactasanantiangiogenicfactorinbcellchroniclymphocyticleukemia |